A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
Recruiting
The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Local Institution - 0228, Fullerton, California +228 locations
Conditions: Sjögren's Syndrome
Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)
Recruiting
To compile characteristics of real-world outcomes for Boston Scientific Corporation's commercially approved Deep Brain Stimulation (DBS) Systems, when used according to the applicable Directions for Use, for the treatment of Essential Tremor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: A.o. LKH Univ.-Kliniken Innsbruck, Innsbruck, Not set +19 locations
Conditions: Essential Tremor
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
Recruiting
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms. The therapies being assessed in this sub-study are risankizumab and lutiki... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Newport Huntington Medical Group /ID# 272764, Huntington Beach, California +21 locations
Conditions: Psoriatic Arthritis
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Recruiting
This study is being done to answer the following question: Can the addition of a new drug to the usual treatment lower the chance of primary central nervous system lymphoma growing or spreading? This study is being done to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as the care most people get for Primary Central Nervous System Lymphoma (PCNSL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta +6 locations
Conditions: Non-hodgkin Lymphoma
Tracking Results of Ablations to Combat AF Registry Generation 2
Recruiting
The primary objective of the TRAC-AF Registry is to capture real-world safety and effectiveness data on AtriCure devices used to conduct concomitant open heart and/or hybrid ablation, and management of the Left Atrial Appendage concomitant to a cardiac ablation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Huntsville Hospital, Huntsville, Alabama +22 locations
Conditions: Atrial Fibrillation
LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma
Recruiting
This study is being done to answer the following question: Can the chance of melanoma growing or spreading be lowered by receiving a treatment called LND101 for Fecal Microbiota Transplant (FMT) in addition to the usual immunotherapy treatment called Immune Checkpoint Blockade (ICB)? FMT treatment changes the bacteria in your gut called the microbiome.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario +7 locations
Conditions: Melanoma
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
Recruiting
The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Dermatology Research Associate, Los Angeles, California +33 locations
Conditions: Atopic Dermatitis
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
Recruiting
This is an open-label study to be conducted in adults with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (SHTG). Each participant must have completed all required visits per protocol in the parent study AROAPOC3-3001 (NCT05089084), AROAPOC3-3003 (NCT06347003), AROAPOC3-3004 (NCT06347016) or AROAPOC3-3009 (NCT06347133). All eligible participants will receive plozasiran administered subcutaneously (SC) approximately every 3 months for 24 months. Participants will be counseled to remai... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Research Site 1, Miami Lakes, Florida +6 locations
Conditions: Hypertriglyceridemia
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
Recruiting
To compile characteristics of real-world clinical outcomes for Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice, when used according to the applicable Directions for Use - and - To evaluate the economic value and technical performance of Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Physicians Research Group, LLC, Phoenix, Arizona +111 locations
Conditions: Pain
Adding Chondrus Crispus Seaweeds to a Meal: Effect on Sensory Perception, Physical Comfort, Satiety and Food Intake
Recruiting
The study investigates the sensory characteristics, consumer perception and the effect on satiety and food intake of the meal with added Chondrus crispus seaweed produced by Acadian Seaplants in Atlantic Canada.
Gender:
MALE
Ages:
Between 19 years and 35 years
Trial Updated:
08/11/2025
Locations: Appetite Lab, Halifax, Nova Scotia
Conditions: Satiety and Food Intake, Sensory Evaluation, Physical Comfort
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Recruiting
This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027 or CN012-0056. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 study, 14-week CN012-0027 study or 14-week CN012-0056 study will be eligible to enroll in CN012-0028. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's Disease.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
08/11/2025
Locations: Local Institution - 1029, Homewood, Alabama +382 locations
Conditions: Psychosis Associated With Alzheimer's Disease
LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery
Recruiting
To evaluate the percentage of subjects with AKI within 7 days following on-pump cardiac surgery defined by the KDIGO (Kidney Disease: Improving Global Outcomes) criteria: 1. Increase in baseline (pre-surgery) serum creatinine (SCr) by ≥26.5 μmol/L (≥0.3 mg/dL) within 7 days; OR 2. Increase in baseline SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the first 7 days following surgery; OR 3. Urine output \< 0.5 mL/kg/h for \>6 hours.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Cumming School of Medicine & Libin Cardiovascular Centre, University of Calgary, Calgary, Alberta +7 locations
Conditions: Acute Kidney Injury, Cardiac Surgery